Teitelbaum receives MERIT award to extend research

Steven L. Teitelbaum, M.D., has been awarded a $1.71 million MERIT award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.

AIDS drug may reduce bone loss in young men with HIV

Ritonavir may slow bone loss in AIDS patients.In a collaborative study initiated by their clinical colleagues, scientists at the School of Medicine have shown that the AIDS drug ritonavir suppresses the creation and activity of cells that dismantle bone, potentially slowing bone loss and lowering the risk of osteoporosis in AIDS patients. The findings may encourage clinicians to consider permanently keeping ritonavir or a similar bone-sparing drug in the changing mixture of treatments for AIDS patients.